SCHEMBL22924871

SCHEMBL22924871

CCC(C(=O)OC)c1cncc(Cl)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSA P10619 1/20 0.35
CTPS1 P17812 1/20 0.34
L3MBTL1 Q9Y468 3/20 0.33
NOS3 P29474 2/20 0.33
NOS1 P29475 2/20 0.33
NOS2 P35228 2/20 0.33
S1PR3 Q99500 1/20 0.32
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
GRM5 P41594 1/20 0.31
LMNA P02545 1/20 0.31
HTT P42858 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CSF1R P07333 2/20 0.31
CDK2 P24941 2/20 0.31
ALDH1A1 P00352 1/20 0.31
FFAR2 O15552 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30416055 1.00 CTSA (0.35) CTSACTPS1L3MBTL1NOS3NOS1
SCHEMBL24768615 0.88 LMNA (0.36) CTSACTPS1MAPTKMT2ALMNA
SCHEMBL16419566 0.88 LMNA (0.36) CTSACTPS1MAPTKMT2ALMNA
SCHEMBL21381538 0.83 AKR1C3 (0.37) CTSACTPS1S1PR3MEN1KMT2A
SCHEMBL26122997 0.81 MAPK1 (0.39) CTSAL3MBTL1S1PR3MEN1MAPT
SCHEMBL30556962 0.81 MAPK1 (0.39) CTSAL3MBTL1S1PR3MEN1MAPT
SCHEMBL21392156 0.78 CTSA (0.34) CTSAL3MBTL1S1PR3MEN1MAPT
SCHEMBL21381606 0.77 MAPK1 (0.37) CTSAL3MBTL1S1PR3MEN1MAPT
SCHEMBL21381662 0.76 CTSA (0.34) CTSAL3MBTL1MEN1MAPTKMT2A
SCHEMBL2580431 0.75 ALDH1A1 (0.38) CTSAMEN1MAPTKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282756-A1 Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors STEP PHARMA S.A.S. (FR) 2025-09-11 US disclosed
US-12371419-B2 Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors STEP PHARMA S.A.S. (FR) 2025-07-29 US disclosed
US-20250066324-A1 AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORS STEP PHARMA S.A.S. (FR) 2025-02-27 US disclosed
EP-3768674-B1 AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS STEP PHARMA S A S (FR) 2024-01-03 EP disclosed
US-20230192673-A1 Compounds STEP PHARMA S.A.S. (FR) 2023-06-22 US disclosed
US-20230192673-A1 Compounds STEP PHARMA S.A.S. (FR) 2023-06-22 US disclosed
US-20230192673-A1 Compounds STEP PHARMA S.A.S. (FR) 2023-06-22 US disclosed
US-20210387965-A1 Compounds STEP PHARMA S.A.S. (FR) 2021-12-16 US disclosed
US-20210024507-A1 Compounds STEP PHARMA S A S (FR) 2021-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371419-B2 Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors CTPS1, CTPS2, TYMS CTSA 2824/4885CTPS1 1/4885L3MBTL1 4242/4885
US-20250282756-A1 Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors CTPS1, CTPS2, TYMS CTSA 2672/4885CTPS1 1/4885L3MBTL1 4238/4885
US-20250066324-A1 AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORS CTPS1, CTPS2, TYMS CTSA 2824/4885CTPS1 1/4885L3MBTL1 4242/4885
US-20210024507-A1 Compounds CYP1A1, UGT1A1, CYP1A2 CTSA 4023/4885CTPS1 2586/4885L3MBTL1 3518/4885
US-20230192673-A1 Compounds CYP1A1, UGT1A1, CYP1A2 CTSA 4023/4885CTPS1 2586/4885L3MBTL1 3518/4885
US-20210387965-A1 Compounds CYP1A1, UGT1A1, CYP1B1 CTSA 4137/4885CTPS1 2704/4885L3MBTL1 3566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.